Canadian researchers hunt for a better way to personalize pancreatic cancer treatment
NCT ID NCT04472910
Summary
This study aims to learn if measuring a specific protein (GATA6) in a patient's tumor can help doctors predict who will benefit most from a specific chemotherapy regimen given before and after surgery for pancreatic cancer. It involves 84 patients across Canada with early-stage, operable pancreatic cancer. The goal is to gather knowledge to help future patients receive more personalized treatment plans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BC Cancer Agency Vancouver
Vancouver, British Columbia, Canada
-
Jewish General Hospital
Montreal, Quebec, Canada
-
Kingston Health Sciences Centre
Kingston, Ontario, Canada
-
London Health Sciences Centre
London, Ontario, Canada
-
Ottawa Hospital
Ottawa, Ontario, Canada
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2N9, Canada
-
Sunnybrook Hospital/Odette Cancer Centre
Toronto, Ontario, Canada
-
Unity Health (St. Joseph's and St. Michael's)
Toronto, Ontario, Canada
Conditions
Explore the condition pages connected to this study.